Orris

Middle path regimen for tb spine

Reading File
Reading File
Searching the Web

Tuli middle path regimen tuberculosis spine treatment indications surgery

Searching PubMed

spinal tuberculosis management

Finding Sources
Reading File
Reading Web Page

https://www.ncbi.nlm.nih.gov/pubmed/46867

Reading File
Tuli’s middle-path regimen for spinal tuberculosis (Pott disease) means primarily conservative treatment, with surgery reserved for clear indications rather than performed routinely.

Components

  1. Antitubercular chemotherapy
    • Start standard multidrug anti-TB treatment based on local/national guidelines and drug-susceptibility testing where possible.
    • Obtain tissue diagnosis by image-guided biopsy/culture or PCR when feasible, particularly to detect drug resistance.
  2. Rest and protection of the spine
    • Initial bed rest during the painful/acute phase.
    • Appropriate spinal brace or orthosis, followed by gradual mobilisation once pain and stability permit.
    • Nutrition, correction of anemia, and management of comorbidities.
  3. Close clinical and radiological follow-up
    • Monitor pain, constitutional symptoms, neurological status, spinal alignment/kyphosis, inflammatory markers, and imaging as indicated.
    • Watch carefully for progressive deformity, especially in children.
  4. Selective surgery only when indicated Surgery is considered for:
    • Progressive or severe neurological deficit, especially with cord compression
    • Failure to improve or deterioration despite adequate chemotherapy
    • Mechanical instability or painful severe kyphosis/progressive deformity
    • Large epidural, paraspinal, or psoas abscess causing compression or not resolving
    • Diagnostic uncertainty or need for biopsy
    • Drug-resistant disease or extensive vertebral destruction

Core principle

“Drugs first, operation only if necessary.” Tuli showed that many patients, including some with neurological deficits, can improve with effective chemotherapy and supervised conservative care. Surgery is not routine debridement for every case.
Current references still identify multidrug therapy as the foundation; modern practice uses MRI, microbiological confirmation, and earlier stabilization/decompression for instability or neurologic compromise. Campbell’s Operative Orthopaedics, 15th ed., p. 2567. A recent surgical management review similarly reports good outcomes with chemotherapy in most patients, while reserving surgery for complications.
Important: “middle path” is a historical management concept, not a substitute for present-day TB protocols. Any weakness, gait difficulty, bladder/bowel symptoms, or worsening deformity requires urgent spine specialist assessment.

Plstell regimen followed in india

Reading File
Searching the Web

India National TB Elimination Programme extrapulmonary spinal tuberculosis treatment regimen drug susceptible 2025 guidelines

Finding Sources
Searching PubMed

spinal tuberculosis treatment India

In India, for drug-susceptible spinal TB, the NTEP regimen is usually:
PhaseDurationDrugs
Intensive phase2 monthsH + R + Z + E
Continuation phase10 monthsH + R + E
Written as: 2 HRZE / 10 HRE
Total duration: 12 months, given daily, in weight-band based fixed-dose combinations.
  • H: isoniazid
  • R: rifampicin
  • Z: pyrazinamide
  • E: ethambutol
This longer continuation phase applies specifically to neuro-TB and spinal TB under the Indian program. The NTEP treatment guidance states that the continuation phase is extended to 10 months for spinal TB. For extrapulmonary TB otherwise, treatment is generally the same as pulmonary TB, as described in the NTEP EPTB guidance.
Before/during treatment: obtain biopsy/CBNAAT and culture with drug-susceptibility testing where feasible, especially before assuming drug-sensitive disease. In spinal TB, MRI and regular neurological/deformity assessment are important. If rifampicin resistance or MDR-TB is found, do not use this regimen; treatment must follow the current NTEP DR-TB guideline.
Surgery is added only for indications such as progressive neurological deficit, instability, major/progressive kyphosis, large compressive abscess, or poor response to adequate ATT.

What is the current NTEP regimen for rifampicin-resistant spinal TB?

Reading File
Reading File
Searching the Web

site:tbcindia.mohfw.gov.in National Guidelines Management Drug Resistant TB 2025 rifampicin-resistant extrapulmonary spinal TB BPaLM regimen duration

Finding Sources
Searching PubMed

rifampicin-resistant tuberculosis BPaLM extrapulmonary

Reading Web Page

https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/Nat…

Reading Article

PMID: 39813501

Searching the Web

"spinal TB" "BPaLM" India NTEP eligibility

Reading Web Page

https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/Nat…

Reading Web Page

https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/Nat…

For rifampicin-resistant spinal TB, NTEP treats it as MDR/RR-TB. However, spinal/skeletal TB is classified as severe extrapulmonary TB and is not eligible for the 6-month BPaLM regimen. It is also generally not suitable for the 9-11 month shorter oral regimen.

Current NTEP approach

Individualized longer all-oral M/XDR-TB regimen for 18-20 months, designed by the N/DDR-TB Centre/committee according to full drug-susceptibility testing.
The preferred longer regimen is built using effective drugs, usually:
  • Bedaquiline (Bdq)
  • Levofloxacin or moxifloxacin (Lfx/Mfx), only if fluoroquinolone-susceptible
  • Linezolid (Lzd)
  • Clofazimine (Cfz)
  • Cycloserine or terizidone (Cs/Tzd)
Additional or substitute drugs are chosen according to DST, prior drug exposure, adverse effects, and availability. The regimen must contain at least four likely effective agents, using the NTEP grouping and replacement sequence.

Practical sequence

  1. Confirm RR-TB on NAAT.
  2. Obtain specimen for culture and extended DST, including fluoroquinolone resistance and resistance to bedaquiline, linezolid, clofazimine and other relevant drugs where available.
  3. Start the 18-20 month longer oral regimen under the DR-TB centre.
  4. Obtain spine MRI and assess urgently for neurological deficit, instability, epidural compression, abscess, or progressive kyphosis. Add drainage/decompression/stabilization if indicated.
The 2024 NTEP DR-TB guideline explicitly lists “spinal/skeletal TB” among severe extrapulmonary MDR-TB forms excluded from BPaLM eligibility. It directs patients who are ineligible for short regimens to the longer oral M/XDR-TB regimen, individualized to DST results. See the NTEP DR-TB guideline.
Do not use 2 HRZE/10 HRE or empirically prescribe BPaLM for confirmed RR spinal TB. This needs specialist-managed treatment because linezolid toxicity, QT prolongation, neuropathy, hepatic effects, and drug interactions require structured monitoring.
This is a shared conversation. Sign in to Orris to start your own chat.